Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
8U4kGCSX07ebBJPZ
